1. Home
  2. MXCT

as of 02-24-2026 9:54am EST

$0.76
+$0.01
+1.26%
Stocks Health Care Biotechnology: Electromedical & Electrotherapeutic Apparatus Nasdaq

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Founded: 1999 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 160.0M IPO Year: 2021
Target Price: $7.50 AVG Volume (30 days): 1.5M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.33 EPS Growth: -5.41
52 Week Low/High: $0.64 - $3.69 Next Earning Date: 04-06-2026
Revenue: $38,627,000 Revenue Growth: -6.44%
Revenue Growth (this year): -7.5% Revenue Growth (next year): 9.64%
P/E Ratio: -2.28 Index: N/A
Free Cash Flow: -29261000.0 FCF Growth: N/A

Share on Social Networks: